Misplaced Pages

ZD6126

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
ZD6126
Skeletal formula
Ball-and-stick model
Clinical data
Other namesANG 453; AZD 6126; N-Acetylcolchicinol dihydrogenphosphate
Identifiers
IUPAC name
  • Phosphoric acid mono-(5-acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzocyclohepten-3-yl) ester
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H24NO8P
Molar mass437.385 g·mol
3D model (JSmol)
SMILES
  • CC(=O)N1CCC2=CC(=C(C(=C2C3=C1C=C(C=C3)OP(=O)(O)O)OC)OC)OC
InChI
  • InChI=1S/C20H24NO8P/c1-11(22)21-16-8-5-12-9-17(26-2)19(27-3)20(28-4)18(12)14-7-6-13(10-15(14)16)29-30(23,24)25/h6-7,9-10,16H,5,8H2,1-4H3,(H,21,22)(H2,23,24,25)/t16-/m0/s1
  • Key:UGBMEXLBFDAOGL-INIZCTEOSA-N
  (what is this?)  (verify)

ZD6126 is a vascular-targeting agent and a prodrug of N-acetylcolchinol, related to colchicine. It has shown promising results on tumors in mice.

A phase I clinical trial identified gastrointestinal and cardiac effects as limiting dosing. Two phase II clinical trials were suspended investigating ZD6126 in metastatic renal cell carcinoma and metastatic colorectal cancer.

ZD6126 was being investigated by AstraZeneca as a vascular disrupting agent (VDA). However, the trials were halted, after it became apparent that ZD6126 was too cardiotoxic at the required doses.

References

  1. "ZD6126". NCI Drug Dictionary. U.S. National Cancer Institute.
  2. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S (July 2002). "Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice". Cancer Research. 62 (13): 3711–5. PMID 12097279.
  3. LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, et al. (April 2008). "Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors". Investigational New Drugs. 26 (2): 159–67. doi:10.1007/s10637-008-9112-9. PMID 18219445. S2CID 40419869.
  4. "ZD6126". ClinicalTrialsGov. U.S. National Library of Medicine.
  5. Lippert JW (January 2007). "Vascular disrupting agents". Bioorganic & Medicinal Chemistry. 15 (2): 605–15. doi:10.1016/j.bmc.2006.10.020. PMID 17070061.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: